ERBB2 and breast carcinoma: Although molecular or genetic measures of prognosis may become increasingly important in IBC risk stratification in the near future, the only three mandatory breast cancer biomarkers are still ER-, PR- and HER2-receptor status, despite the massive investment of time and money into development of new biomarkers [4].